FTSE MIB
34.781,91 +124,56 (+0,36%) Dow Jones
39.512,84 +837,14 (+2,16%) Nasdaq
16.340,87 +184,57 (+1,14%) Nikkei 225
38.179,46 -49,65 (-0,13%) Petrolio
78,49 +0,23 (+0,29%) Bitcoin EUR
58.301,56 +1.687,25 (+2,98%)
Veru Inc. (VERU)
Dopo ore:
| Chiusura precedente | 1,3700 |
| Aperto | 1,3800 |
| Denaro | 1,3200 x 1800 |
| Lettera | 1,3500 x 900 |
| Min-Max giorno | 1,3300 - 1,4500 |
| Intervallo di 52 settimane | 0,3600 - 1,9200 |
| Volume | |
| Media Volume | 2.530.942 |
| Capitalizzazione | 194,691M |
| Beta (5 anni mensile) | -0,20 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,7000 |
| Prossima data utili | 08 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 28 apr 2014 |
| Stima target 1A | 3,05 |
GlobeNewswireVeru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study
-- In 5 clinical studies involving 968 older men and postmenopausal women with and without muscle wasting, enobosarm has demonstrated the ability to decrease fat mass, increase muscle mass, and improve muscle strength and physical function -- -- Weight-loss drugs like Ozempic, Wegovy, Mounjaro and other GLP-1 drugs cause a significant loss of both fat and muscle; in older obese or overweight patients who may already have low muscle mass, the further drop in muscle mass of all-important muscles i
- GlobeNewswire
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult patients with any type of virus induced ARDS including the “tripledemic viruses”: Influenza, RSV, and SARS-CoV-2-- -- Based on high mortality rate for viral ARDS, expected sabizabulin Phase 3 study size is 408 patients with all-cause mortality at Day 60 as the primary endpoint-- --The Company plans to conduct the “all comers” viral ARDS Phase 3 study instead of th
- GlobeNewswire
Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023
MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference to be held at the InterContinental New York, Barcl
